NCT03653156

Brief Summary

The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:

  1. 1.To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data.
  2. 2.To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia.
  3. 3.To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia).
  4. 4.To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis.
  5. 5.To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models.
  6. 6.To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people.
  7. 7.To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients，which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up.
  8. 8.To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies.
  9. 9.To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia.
  10. 10.To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
143mo left

Started Jan 2000

Longer than P75 for all trials

Geographic Reach
1 country

65 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Jan 2000Jan 2038

Study Start

First participant enrolled

January 1, 2000

Completed
18.7 years until next milestone

First Submitted

Initial submission to the registry

August 23, 2018

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 31, 2018

Completed
19.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2038

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2038

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

38 years

First QC Date

August 23, 2018

Last Update Submit

March 19, 2026

Conditions

Mild Cognitive Impairment(MCI)Alzheimer Disease, Late OnsetFamilial Alzheimer Disease (FAD)Vascular Dementia (VaD)Normal ControlNon-Alzheimer Degenerative Dementia

Outcome Measures

Primary Outcomes (5)

  • The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design

    an average of 2 years

  • The conversion rate of normal to MCI to AD in Chinese

    an average of 2 years

  • The biomarkers for normal (pre-MCI), MCI and AD diagnosis

    Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.

    an average of 2 years

  • The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels

    Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.

    an average of 2 years

  • The effective non-pharmacologic treatment(NPT) intervention

    The effective non-pharmacologic treatment(NPT) intervention- including lifestyle(diet and sleep habits, smoking, drinking and social networking), health products, exercise habits, cognitive training, risk factor control- on APOE ε4 carriers, MCI and dementia patients using questionnaire.

    an average of 2 years

Study Arms (6)

Mild cognitive impairment (MCI) and its subtypes

MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.

Sporadic Alzheimer's disease (SAD)

SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.

Familial Alzheimer's disease (FAD)

FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.

Vascular dementia(VaD）

VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.

Normal control

Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.

Non-Alzheimer degenerative dementia

Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Mild cognitive impairment (MCI) and its subtypes、Sporadic Alzheimer's disease (SAD)、 Familial Alzheimer's disease (FAD)、Vascular dementia (VaD)、Normal control in Community population and Hospital population.

You may qualify if:

  • Diagnosis according to 2004 Peterson's MCI criteria.
  • CDR = 0.5.
  • Memory loss is prominent, and may also be with other cognitive domain dysfunction.
  • Insidious onset, slow progress.
  • Not reaching the level of dementia.

You may not qualify if:

  • With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).
  • Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • Mental and neurodevelopmental retardation.
  • Contraindications to MRI.
  • Suffering from a disease that cannot be combined with cognitive examination.
  • Refuse to draw blood.
  • Refuse to sign the informed consent at baseline
  • (2) Sporadic Alzheimer's disease (SAD)
  • Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
  • Subjects and their informed persons can complete relevant and follow- up examinations.
  • Subjects or their authorized legal guardians sign the informed consent.
  • With a family history of dementia.
  • Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
  • Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
  • +42 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (65)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

RECRUITING

Beijing Geriatric Hospital

Changping, Beijing Municipality, China

RECRUITING

Beijing Chao Yang Hospital

Chaoyang, Beijing Municipality, China

RECRUITING

China-Japan Friendship Hospital

Chaoyang, Beijing Municipality, China

RECRUITING

Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

Fengtai, Beijing Municipality, China

RECRUITING

Chinese PLA General Hospital

Haidian, Beijing Municipality, China

RECRUITING

Fu Xing Hospital, Capital Medical University

Haidian, Beijing Municipality, China

RECRUITING

Peking University Third Hospital

Haidian, Beijing Municipality, China

RECRUITING

Peking Union Medical College Hospital

Xicheng, Beijing Municipality, China

RECRUITING

Peking University First Hospital

Xicheng, Beijing Municipality, China

RECRUITING

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Yuzhong, Chongqing Municipality, China

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University

Yuzhong, Chongqing Municipality, China

RECRUITING

Fujian Medical University Union Hospital

Fujian, Guangdong, China

RECRUITING

Guangzhou Psychiatric Hospital

Guangzhou, Guangdong, China

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Zhongshan, Guangdong, China

RECRUITING

First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

RECRUITING

The Affiliated Hospital Of Guizhou Medical University

Guiyang, Guizhou, China

RECRUITING

Handan Central Hospital

Handan, Hebei, China

RECRUITING

First Hospital of Shijiazhuang City

Shijiazhuang, Hebei, China

RECRUITING

Tangshan Worker's Hospital

Tangshan, Hebei, China

RECRUITING

Hebei General Hospital

Zhijiazhuang, Hebei, China

RECRUITING

First Affiliated Hospital of Harbin Medical University

Haerbin, Heilongjiang, China

RECRUITING

Kaifeng Central Hospital

Kaifeng, Henan, China

RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, China

RECRUITING

People's Hospital of Zhengzhou

Zhengzhou, Henan, China

RECRUITING

People's Hospital Affiliated Hubei Medical University

Wuhan, Hubei, China

RECRUITING

Tongji Hospital

Wuhan, Hubei, China

RECRUITING

The Third Xiangya Hospital of Central South University

Wuhan, Hunan, China

RECRUITING

Wuhan University Zhongnan Hospital

Wuhan, Hunan, China

RECRUITING

Xiangya Hospital of Central South University

Wuhan, Hunan, China

RECRUITING

Nantong University Affiliated Hospital

Nantong, Jiangsu, China

RECRUITING

Subei People's Hospital of Jiangsu

Subei, Jiangsu, China

RECRUITING

Mineral General Hospital, Xuzhou

Xuzhou, Jiangsu, China

RECRUITING

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

RECRUITING

China-Japan friendship Hospital of Jilin university

Changchun, Jilin, China

RECRUITING

The First Hospital of Jilin University

Changchun, Jilin, China

RECRUITING

Changda Hospital, Anshan

Anshan, Liaoning, China

RECRUITING

Affiliated Zhongshan hospital of Dalian university

Dalian, Liaoning, China

RECRUITING

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

RECRUITING

First Hospital of China Medical University

Shenyang, Liaoning, China

RECRUITING

Baotou Central Hospital

Baotou, Nei Monggol, China

RECRUITING

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

RECRUITING

The People's Hospital of Ningxia

Yinchuan, Ningxia, China

RECRUITING

Qilu Hospital of Shandong University

Jinan, Shandong, China

RECRUITING

Shandong Provincial Hospital

Jining, Shandong, China

RECRUITING

Qilu Hospital of Shandong University (Qingdao)

Qingdao, Shandong, China

RECRUITING

QingDao Municipal Hospital

Qingdao, Shandong, China

RECRUITING

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

RECRUITING

The 88th Hospital of PLA

Tai’an, Shandong, China

RECRUITING

Shanghai Changzheng Hospital

Huangpu, Shanghai Municipality, China

RECRUITING

Ruijin Hospital

Luwan, Shanghai Municipality, China

RECRUITING

RenJi Hospital

Putong, Shanghai Municipality, China

RECRUITING

The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

RECRUITING

First Affiliated Hospital Xi'an Jiaotong University

Xi’an, Shanxi, China

RECRUITING

Tang-Du Hospital

Xi’an, Shanxi, China

RECRUITING

Affiliated Hospital of North Sichuan Medical College

Nanchong, Sichuan, China

RECRUITING

Zigong First People's Hospital

Zigong, Sichuan, China

RECRUITING

Tianjin Huanhu Hospital

Xianshuigu, Tianjin Municipality, China

RECRUITING

Tianjin Medical University General Hospital

Xiaobailou, Tianjin Municipality, China

RECRUITING

Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region

Ürümqi, Xinjiang, China

RECRUITING

First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Shao Yifu Hospital of Zhejiang Medical University

Hangzhou, Zhejiang, China

RECRUITING

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

RECRUITING

Ningbo City Medical Treatment Center Lihuili Hospital

Ningbo, Zhejiang, China

RECRUITING

First Affiliated Hospital of Wenzhou Medical Univeristy

Wenzhou, Zhejiang, China

RECRUITING

Related Publications (46)

  • Zhou A, Jia J. A screen for cognitive assessments for patients with vascular cognitive impairment no dementia. Int J Geriatr Psychiatry. 2009 Dec;24(12):1352-7. doi: 10.1002/gps.2265.

    PMID: 19347838RESULT

  • Zhou A, Jia J. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. J Int Neuropsychol Soc. 2009 Nov;15(6):898-905. doi: 10.1017/S1355617709990816.

    PMID: 19891819RESULT

  • Bai F, Liao W, Watson DR, Shi Y, Yuan Y, Cohen AD, Xie C, Wang Y, Yue C, Teng Y, Wu D, Jia J, Zhang Z. Mapping the altered patterns of cerebellar resting-state function in longitudinal amnestic mild cognitive impairment patients. J Alzheimers Dis. 2011;23(1):87-99. doi: 10.3233/JAD-2010-101533.

    PMID: 20930266RESULT

  • Han Y, Wang J, Zhao Z, Min B, Lu J, Li K, He Y, Jia J. Frequency-dependent changes in the amplitude of low-frequency fluctuations in amnestic mild cognitive impairment: a resting-state fMRI study. Neuroimage. 2011 Mar 1;55(1):287-95. doi: 10.1016/j.neuroimage.2010.11.059. Epub 2010 Nov 28.

    PMID: 21118724RESULT

  • Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, Jia XF, Song H, Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol. 2011 Dec;24(4):184-90. doi: 10.1177/0891988711422528.

    PMID: 22228824RESULT

  • Shi FD, Jia JP. Neurology and neurologic practice in China. Neurology. 2011 Nov 29;77(22):1986-92. doi: 10.1212/WNL.0b013e31823a0ed3.

    PMID: 22123780RESULT

  • Han Y, Jia J, Jia XF, Qin W, Wang S. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease. Neurosci Lett. 2012 May 16;516(2):232-6. doi: 10.1016/j.neulet.2012.03.094. Epub 2012 Apr 7.

    PMID: 22503901RESULT

  • Li F, Jia XF, Jia J. The Informant Questionnaire on Cognitive Decline in the Elderly individuals in screening mild cognitive impairment with or without functional impairment. J Geriatr Psychiatry Neurol. 2012 Dec;25(4):227-32. doi: 10.1177/0891988712464822. Epub 2012 Nov 21.

    PMID: 23172761RESULT

  • Song J, Wang S, Tan M, Jia J. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. Neurosci Lett. 2012 Sep 27;526(2):144-9. doi: 10.1016/j.neulet.2012.08.020. Epub 2012 Aug 17.

    PMID: 22922216RESULT

  • Tan M, Wang S, Song J, Jia J. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neurosci Lett. 2012 May 16;516(2):226-31. doi: 10.1016/j.neulet.2012.03.093. Epub 2012 Apr 6.

    PMID: 22503900RESULT

  • Wang F, Shu C, Jia L, Zuo X, Zhang Y, Zhou A, Qin W, Song H, Wei C, Zhang F, Hong Z, Tang M, Wang DM, Jia J. Exploration of 16 candidate genes identifies the association of IDE with Alzheimer's disease in Han Chinese. Neurobiol Aging. 2012 May;33(5):1014.e1-9. doi: 10.1016/j.neurobiolaging.2010.08.004. Epub 2010 Sep 28.

    PMID: 20880607RESULT

  • Wang S, Song J, Tan M, Albers KM, Jia J. Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease. Eur J Neurol. 2012 Jul;19(7):1015-22. doi: 10.1111/j.1468-1331.2012.03670.x. Epub 2012 Feb 16.

    PMID: 22340708RESULT

  • Xing Y, Qin W, Li F, Jia XF, Jia J. Apolipoprotein E epsilon4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33(1):35-42. doi: 10.1159/000336600. Epub 2012 Mar 2.

    PMID: 22398564RESULT

  • Xing Y, Wei C, Chu C, Zhou A, Li F, Wu L, Song H, Zuo X, Wang F, Qin W, Li D, Tang Y, Jia XF, Jia J. Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia. Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):433-8. doi: 10.1177/1533317512454712.

    PMID: 22930700RESULT

  • Li F, Wang F, Jia J. Evaluating the prevalence of dementia in hospitalized older adults and effects of comorbid dementia on patients' hospital course. Aging Clin Exp Res. 2013 Aug;25(4):393-401. doi: 10.1007/s40520-013-0068-z. Epub 2013 Jul 20.

    PMID: 23872925RESULT

  • Xing Y, Qin W, Li F, Jia XF, Jia J. Associations between sex hormones and cognitive and neuropsychiatric manifestations in vascular dementia (VaD). Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):85-90. doi: 10.1016/j.archger.2012.10.003. Epub 2012 Oct 24.

    PMID: 23103091RESULT

  • Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014 Jan;10(1):1-9. doi: 10.1016/j.jalz.2013.01.012. Epub 2013 Jul 18.

    PMID: 23871765RESULT

  • Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X, Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. Alzheimers Dement. 2014 Jul;10(4):439-447. doi: 10.1016/j.jalz.2013.09.008. Epub 2014 Jan 10.

    PMID: 24418053RESULT

  • Qin W, Jia X, Wang F, Zuo X, Wu L, Zhou A, Li D, Min B, Wei C, Tang Y, Xing Y, Dong X, Wang Q, Gao Y, Li Y, Jia J. Elevated plasma angiogenesis factors in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):245-52. doi: 10.3233/JAD-142409.

    PMID: 25690662RESULT

  • Song H, Long H, Zuo X, Yu C, Liu B, Wang Z, Wang Q, Wang F, Han Y, Jia J. APOE Effects on Default Mode Network in Chinese Cognitive Normal Elderly: Relationship with Clinical Cognitive Performance. PLoS One. 2015 Jul 15;10(7):e0133179. doi: 10.1371/journal.pone.0133179. eCollection 2015.

    PMID: 26177270RESULT

  • Jia J, Zuo X, Jia XF, Chu C, Wu L, Zhou A, Wei C, Tang Y, Li D, Qin W, Song H, Ma Q, Li J, Sun Y, Min B, Xue S, Xu E, Yuan Q, Wang M, Huang X, Fan C, Liu J, Ren Y, Jia Q, Wang Q, Jiao L, Xing Y, Wu X; China Cognition and Aging Study (China COAST) Group. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. Alzheimers Dement. 2016 Apr;12(4):446-53. doi: 10.1016/j.jalz.2015.06.1892. Epub 2015 Aug 7.

    PMID: 26256457RESULT

  • Li H, Jia J, Yang Z. Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study. J Alzheimers Dis. 2016 May 7;53(2):487-96. doi: 10.3233/JAD-160119.

    PMID: 27163822RESULT

  • Xing Y, Tang Y, Zhao L, Wang Q, Qin W, Zhang JL, Jia J. Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1029-35. doi: 10.3233/JAD-151158.

    PMID: 27079712RESULT

  • Yuan X, Han Y, Wei Y, Xia M, Sheng C, Jia J, He Y. Regional homogeneity changes in amnestic mild cognitive impairment patients. Neurosci Lett. 2016 Aug 26;629:1-8. doi: 10.1016/j.neulet.2016.06.047. Epub 2016 Jun 23.

    PMID: 27345927RESULT

  • Li D, Hu N, Yu Y, Zhou A, Li F, Jia J. Trajectories of Multidimensional Caregiver Burden in Chinese Informal Caregivers for Dementia: Evidence from Exploratory and Confirmatory Factor Analysis of the Zarit Burden Interview. J Alzheimers Dis. 2017;59(4):1317-1325. doi: 10.3233/JAD-170172.

    PMID: 28759966RESULT

  • Liu Q, Zhu Z, Teipel SJ, Yang J, Xing Y, Tang Y, Jia J. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front Aging Neurosci. 2017 Feb 27;9:47. doi: 10.3389/fnagi.2017.00047. eCollection 2017.

    PMID: 28289381RESULT

  • Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9.

    PMID: 29433981RESULT

  • Li J, Wu L, Tang Y, Zhou A, Wang F, Xing Y, Jia J. Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. BMC Neurol. 2018 May 10;18(1):65. doi: 10.1186/s12883-018-1068-6.

    PMID: 29747584RESULT

  • Qiu Q, Shen L, Jia L, Wang Q, Li F, Li Y, Jia J. A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Abeta42/Abeta40 ratio. J Alzheimers Dis. 2019;69(1):199-212. doi: 10.3233/JAD-181291.

    PMID: 30958370RESULT

  • Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019 Aug;15(8):1071-1080. doi: 10.1016/j.jalz.2019.05.002.

    PMID: 31422798RESULT

  • Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, Wang Q, Yan X, Kong C, Hao J, Wei C, Tang Y, Qin W, Li Y, Wang F, Guo D, Zhou A, Zuo X, Yu Y, Li D, Zhao L, Jin H, Jia J. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease. Alzheimers Dement. 2020 Jan;16(1):178-191. doi: 10.1002/alz.12005.

    PMID: 31914229RESULT

  • Zhao T, Quan M, Jia J. Functional Connectivity of Default Mode Network Subsystems in the Presymptomatic Stage of Autosomal Dominant Alzheimer's Disease. J Alzheimers Dis. 2020;73(4):1435-1444. doi: 10.3233/JAD-191065.

    PMID: 31929167RESULT

  • Quan M, Zhao T, Tang Y, Luo P, Wang W, Qin Q, Li T, Wang Q, Fang J, Jia J. Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer's disease. Alzheimers Res Ther. 2020 Jan 14;12(1):14. doi: 10.1186/s13195-019-0572-2.

    PMID: 31937364RESULT

  • Jia L, Xu H, Chen S, Wang X, Yang J, Gong M, Wei C, Tang Y, Qu Q, Chu L, Shen L, Zhou C, Wang Q, Zhao T, Zhou A, Li Y, Li F, Li Y, Jin H, Qin Q, Jiao H, Li Y, Zhang H, Lyu D, Shi Y, Song Y, Jia J. The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease. Alzheimers Dement. 2020 Dec;16(12):1613-1623. doi: 10.1002/alz.12153. Epub 2020 Sep 3.

    PMID: 32881347RESULT

  • Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, Wei C, Tang Y, Wang Q, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia J. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. Alzheimers Dement. 2021 Jan;17(1):49-60. doi: 10.1002/alz.12166. Epub 2020 Aug 10.

    PMID: 32776690RESULT

  • Han Y, Zhou A, Li F, Wang Q, Xu L, Jia J. Apolipoprotein E epsilon4 allele is associated with vascular cognitive impairment no dementia in Chinese population. J Neurol Sci. 2020 Feb 15;409:116606. doi: 10.1016/j.jns.2019.116606. Epub 2019 Dec 6.

    PMID: 31865187RESULT

  • Qiu Q, Jia L, Wang Q, Zhao L, Jin H, Li T, Quan M, Xu L, Li B, Li Y, Jia J. Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease. Neurobiol Aging. 2020 Jan;85:155.e1-155.e4. doi: 10.1016/j.neurobiolaging.2019.05.018. Epub 2019 May 31.

    PMID: 31235344RESULT

  • Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M, Jiao H, Song Y, Shi Y, Zhang H, Gong M, Wei C, Tang Y, Fang B, Guo D, Wang F, Zhou A, Chu C, Zuo X, Yu Y, Yuan Q, Wang W, Li F, Shi S, Yang H, Zhou C, Liao Z, Lv Y, Li Y, Kan M, Zhao H, Wang S, Yang S, Li H, Liu Z, Wang Q, Qin W, Jia J; COAST Group. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020 Dec;5(12):e661-e671. doi: 10.1016/S2468-2667(20)30185-7.

    PMID: 33271079RESULT

  • Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y, Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, Zhang J, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y, Liang J, Wang Q, Jin H, Wang W, Lu Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, Li Y, Kong C, Li Y, Jiao H, Lu J, Jia J. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain. 2021 Apr 12;144(3):924-937. doi: 10.1093/brain/awaa364.

    PMID: 33188687RESULT

  • Qin W, Zhou A, Zuo X, Jia L, Li F, Wang Q, Li Y, Wei Y, Jin H, Cruchaga C, Benitez BA, Jia J. Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease. Hum Mol Genet. 2021 May 28;30(9):811-822. doi: 10.1093/hmg/ddab090.

    PMID: 33835157RESULT

  • Jia J, Zhao T, Liu Z, Liang Y, Li F, Li Y, Liu W, Li F, Shi S, Zhou C, Yang H, Liao Z, Li Y, Zhao H, Zhang J, Zhang K, Kan M, Yang S, Li H, Liu Z, Ma R, Lv J, Wang Y, Yan X, Liang F, Yuan X, Zhang J, Gauthier S, Cummings J. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ. 2023 Jan 25;380:e072691. doi: 10.1136/bmj-2022-072691.

    PMID: 36696990RESULT

  • Jia J, Zhang Y, Shi Y, Yin X, Wang S, Li Y, Zhao T, Liu W, Zhou A, Jia L. A 19-Year-Old Adolescent with Probable Alzheimer's Disease. J Alzheimers Dis. 2023;91(3):915-922. doi: 10.3233/JAD-221065.

    PMID: 36565128RESULT

  • Li W, Pang Y, Wang Y, Mei F, Guo M, Wei Y, Li X, Qin W, Wang W, Jia L, Jia J. Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer's disease. BMC Med. 2023 Jun 26;21(1):223. doi: 10.1186/s12916-023-02930-7.

    PMID: 37365538RESULT

  • Quan M, Wang Q, Qin W, Wang W, Li F, Zhao T, Li T, Qiu Q, Cao S, Wang S, Wang Y, Jin H, Zhou A, Fang J, Jia L, Jia J. Shared and unique effects of ApoEepsilon4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimers Res Ther. 2023 Feb 28;15(1):40. doi: 10.1186/s13195-023-01192-y.

    PMID: 36850008RESULT

  • Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, Ding J, Li Y, Zhao B, Lyu J, Yang S, Yan X, Wang Y, Qin W, Wang Q, Li Y, Zhang J, Liang F, Liao Z, Wang S. Biomarker Changes during 20 Years Preceding Alzheimer's Disease. N Engl J Med. 2024 Feb 22;390(8):712-722. doi: 10.1056/NEJMoa2310168.

    PMID: 38381674RESULT

  • Zhao B, Zang P, Quan M, Wang Q, Guo D, Jia J, Wang W. The Effect of APOE epsilon4 on Alzheimer's Disease Fluid Biomarkers: A Cross-Sectional Study Based on the COAST. CNS Neurosci Ther. 2025 Jan;31(1):e70202. doi: 10.1111/cns.70202.

    PMID: 39749650DERIVED

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Plasma, CSF, saliva and biopsy and autopsy

MeSH Terms

Conditions

Cognitive DysfunctionAlzheimer DiseaseDementia, Vascular

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesCerebrovascular DisordersIntracranial ArteriosclerosisIntracranial Arterial DiseasesLeukoencephalopathiesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Jianping Jia, Doctor

    Xuanwu Hospital of Capital Medical University

    STUDY CHAIR

Central Study Contacts

Jianping Jia, Doctor

CONTACT

jiajp@vip.126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
30 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Director

Study Record Dates

First Submitted

August 23, 2018

First Posted

August 31, 2018

Study Start

January 1, 2000

Primary Completion (Estimated)

January 1, 2038

Study Completion (Estimated)

January 1, 2038

Last Updated

March 23, 2026

Record last verified: 2026-03

Locations

CN(65)